Ibrutinib No Longer Approved for MCL, MZL: How This Change Will Affect Patients
The withdrawn approvals of ibrutinib for relapsed/refractory MCL and MZL are likely to have a limited impact on patients, experts say.
All articles by Mary Ellen Schneider
In the COVID-19 Era, Are In-Person Conferences Worth the Risks?
As the COVID-19 pandemic wears on, oncology professionals must decide if attending conferences in person is worth the risks.
- Loading...
Loading...
Next post in Oncology
Loading... 
Loading...